Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

    Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

    Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\5OFghcA>? NIDsbpdKSzVyPUGzPU4zOOLCidMx5qCKPS57NTFOwG0> NFTyW|IzPTl4MEK4Ni=>
KellyCis83 NXTQfHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T2TVQ5KGh? MnXSTWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> M13ZZVI2QTZyMkiy
SK-N-AS M1jyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftOFghcA>? M{X0RWlEPTB;MkK3Mlcx6oDLwsJihKkzOi5zNTFOwG0> NED0e2czPTl4MEK4Ni=>
SK-N-ASCis24 M3rIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe5R|Y1QCCq MUPJR|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=> NWDSSFA6OjV7NkCyPFI>
CHP-212 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvCUmdVPDhiaB?= NW\odnlXUUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=> MnPaNlU6PjB{OEK=
CHP-212Cis100 M4\SdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K5fFQ5KGh? NXu5WJI3UUN3ME25MlU26oDLwsJihKkxNjh6IN88US=> MVeyOVk3ODJ6Mh?=
U87  MWPGeY5kfGmxbjDBd5NigQ>? NXPodHlGOTByIN88US=> NH\XcWgzPC15MjDo MYjpcoR2[2W|IFTjVlEh\XiycnXzd4lwdg>? M2XSPVI2QDB6OE[4
LN229 M2XvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvGfmgxNTVyIN88US=> NHjLPGVKSzVyPUG2JO69VQ>? MXeyOVc2ODJ5Mx?=
TR-LN229 NIjJe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfDZYoxNTVyIN88US=> NUnuSVRiUUN3ME23O{DPxE1? MX:yOVc2ODJ5Mx?=
U87  MV3BdI9xfG:|aYOgRZN{[Xl? MnfyNQKBmzJyMPMAjeK2VQ>? NI[2V2kzPCCq NHfFdmJmdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>? M{PGOlI2PjhzNk[4
U251MG M1fCRWFxd3C2b4Ppd{BCe3OjeR?= M3zn[FExOMLizszN M161O|Q5KGh? MV\QRnM> MVXpcoR2[2W|IHHwc5B1d3Orcx?= MoHaNlU3QDB2NkS=
U87MG NY\CcYY{SXCxcITvd4l{KEG|c3H5 NX;vOYduOTBywrFOwG0> MXq0PEBp MWPQRnM> Mm\xbY5lfWOnczDhdI9xfG:|aYO= MoTVNlU3QDB2NkS=
U87 NELjW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO3WYc2OC1|NUCg{txO NXzr[plqPDkEoHlCpC=> NFXobW9qdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? NELqNI4zPTV3NEKyNy=>
U118  M1L4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTVOnBKPTBvM{WwJO69VQ>? NHvUZmI1QMLiaNMg M1jBWIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 M3XOe|I2PTV2MkKz
U87 MYLGeY5kfGmxbjDBd5NigQ>? NV\tcIRiOjVyL{O1NEDPxE1? NGDJRow1QMLiaNMg NEDuS2VmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? MkDyNlU2PTR{MkO=
U118  NELKbHVHfW6ldHnvckBCe3OjeR?= NVLNZm56OjVyL{O1NEDPxE1? NIH4bIo1QMLiaNMg M{foNIVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? M3\WNFI2PTV2MkKz
U87 NVWxUllqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWyNlUxNzN3MDFOwG0> MVO0POKhcMLi MnfnbY5kemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJHMh[W6mIFeyM23DqGOxdILlZZRm\CC5aYToJHROYA>? NFnseJMzPTV3NEKyNy=>
A375 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\NbnE1QMLiaNMg MmfUTWM2OD1{NkWg{txO Ml\3NlU2OjR3NUK=
A2058 NFry[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nmSVQ5yqCqwrC= M2rp[GlEPTB;MUKg{txO NITNUoYzPTV{NEW1Ni=>
M238 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTMOFjDqGkEoB?= NXzHS|Y4UUN3ME20NEDPxE1? MWeyOVUzPDV3Mh?=
M249 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T5ZlQ5yqCqwrC= M4r1fmlEPTB;MkW0JO69VQ>? M4Oye|I2PTJ2NUWy
M21 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn3UFZlPDkEoHlCpC=> M3\wOGlEPTB;MkKxJO69VQ>? MlHpNlU2OjR3NUK=
U251 MkPtR5l1d3SxeHn0fUBCe3OjeR?= NIPnV48zOCEQvF5CpC=> MlvPOFjDqGkEoB?= MonRdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= MWmyOVQ{PDN6MR?=
LN229 MXnDfZRwfG:6aYT5JGF{e2G7 MmjPNlAh|ryPwrC= Mne0OFjDqGkEoB?= NIDhNnVz\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk MWGyOVQ{PDN6MR?=
U373MG-LUC MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDSO|IhcA>? NULxdVN6UUN3ME62NFAh|ryP M4LQ[|I2PDNzOUWz
U87  Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nlTVI2NTJyMDFOwG0> M3PVR|Q5yqCqwrC= M1[3WYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH6ydWszPTRyMEe0OS=>
U251 MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKyOU0zODBizszN NEHW[pc1QMLiaNMg MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{\hUFI2PDByN{S1
U251 M4PHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNFAuPDByIN88US=> M3\RZ|czNzl4IHi= NHTW[Vh1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= NHezVGkzPTN5NUK3NS=>
U373 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\k[GVROTByLUSwNEDPxE1? NXjRcG81PzJxOU[gbC=> M{CyN5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NYL4[ngzOjV|N{WyO|E>
U343 M2nRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLzNVAxNTRyMDFOwG0> NYXjOnlWPzJxOU[gbC=> M4DHXJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NYKwZY1nOjV|N{WyO|E>
U87MG-luc2 NEnk[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVftdpNtOTByLUSwNEDPxE1? NUPpR3FnPzJxOU[gbC=> M3vpdpRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MX[yOVM4PTJ5MR?=
U87 NXL5e5VCTnWwY4Tpc44hSXO|YYm= NFjOO|gzODBizszN M3LDRlQ5KGh? NGTUVo9qdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w NV;jbIdbOjV|M{e3NlE>
U251 M4DKU2Z2dmO2aX;uJGF{e2G7 NFzGSJIzODBizszN MnrJOFghcA>? MlrBbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NVnhTlNMOjV|M{e3NlE>
A172 NIj4U21HfW6ldHnvckBCe3OjeR?= M{j4RlIxOCEQvF2= M4DTUlQ5KGh? NVH5cYRMcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= M3z5PFI2OzN5N{Kx
U251 NIezTFZHfW6ldHnvckBCe3OjeR?= M2myPFIxOCEQvF2= MkHROFghcA>? NUTGU|JOcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= NID2Z3AzPTN|N{eyNS=>
A172 MlrySpVv[3Srb36gRZN{[Xl? NIDacWozODBizszN MmnQOFghcA>? MWLpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz MXOyOVM{Pzd{MR?=
U87 NGGxPJVHfW6ldHnvckBCe3OjeR?= NXLrTJJNOjByIN88US=> NGPCfWozPC95Mj:xNlAhcA>? NEGxS3hqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? NW\tZXZmOjV|M{e3NlE>
U251 MnfWSpVv[3Srb36gRZN{[Xl? NFzrd4IzODBizszN M3nqVFI1Nzd{L{GyNEBp NIHPTFdqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? NYjxT|lHOjV|M{e3NlE>
A172 NEXQXnBHfW6ldHnvckBCe3OjeR?= MV6yNFAh|ryP MYKyOE84Oi9zMkCgbC=> M3XNc4lv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? M1;2PVI2OzN5N{Kx
SNB19V NVvzfVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\YRXNyPyCm Mnu1SG1UVw>? M1u5O2dKPTB;M{WuO:KyOTJizszN NIfPS4gzPTJ5N{S0NS=>
SNB19M MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;JOpk4KGR? M{PK[GROW09? MlXyS2k2OD12NkmuPeKyQDhizszN MUmyOVI4PzR2MR?=
SNB19VR MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0U5cyPyCm MWHEUXNQ NWrJWHE3T0l3ME2yPFAvOsLzMUig{txO MnvtNlUzPzd2NEG=
U373V Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnqSYF7PyCm MoC4SG1UVw>? NI[xUWxIUTVyPU[4MlDDuTN{IN88US=> M4TiSlI2Ojd5NESx
U373M MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLNO{Bl MmHISG1UVw>? NXHwOIN6T0l3ME2zOlgvP8LzOE[g{txO M13TPVI2Ojd5NESx
U373VR NInmb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvO{Bl MUnEUXNQ NYPlPGgxT0l3ME2yPFgvQMLzM{Og{txO MYiyOVI4PzR2MR?=
U87MG NYX3SHpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK3JIQ> MnXvSG1UVw>? MXXHTVUxRTN6LkRCtVIxKM7:TR?= MYKyOVI4PzR2MR?=
HCT116 NYPjcYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vkfVch\A>? NYTaR4ZTTE2VTx?= M1e3V2dKPTB;NUe5MlnDuTN{IN88US=> MonLNlUzPzd2NEG=
DLD1 M3XOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrNO{Bl NHyzT5FFVVOR NHfROGNIUTVyPUWwNU41yrF7MzFOwG0> MYCyOVI4PzR2MR?=
MRC5 NXfrU4FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHyO{Bl MUfEUXNQ MXvHTVUxRTR2OT60xtE5KM7:TR?= MV6yOVI4PzR2MR?=
SNB19V  NYrzeohRTnWwY4Tpc44hSXO|YYm= M3fM[FExOCEQvF5CpHROYg>? NUf2UHl4OC15MjDo M3mybIlv[3KnYYPld{DPu0h{QWig[ZhxemW|c3nvckBj\XS5ZXXuJFE3KGGwZDC3NkBp M1\C[VI2Ojd5NESx
T98G  NH;3dHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnmO5A2NzFyL{G1JO69VQ>? NWHENlYyOjUEoHi= MV7pcoR2[2W|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?= NUfaUFlSOjV{NkK5OlE>
U251  NY\JepppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX21M|ExNzF3IN88US=> NEjoTpAzPMLiaB?= MnPWbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= NXi4RoVMOjV{NkK5OlE>
T98G  MlTiSpVv[3Srb36gRZN{[Xl? MWGxOUDPxE1? MofkNlTDqGh? NYXBOYtJcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz MnfrNlUzPjJ7NkG=
U251  MVfGeY5kfGmxbjDBd5NigQ>? MmDONVUh|ryP M{PKS|I1yqCq MlHVbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| M{nUbVI2OjZ{OU[x
U-87 MG MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK3NkBp MULJR|UxRTBwOUOgcW3DqA>? Mn;zNlUzPDV|M{K=
U-118 MG NUj2Vll1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS1O|IhcA>? NWPaU5lOUUN3ME2xMlA2KG2PwrC= MVqyOVI1PTN|Mh?=
U87 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISxcVIzPCCq M4HsR2lEPTB;Mk[wMlM1KM7:TdMg M1vNXlI2OTd|MkOz
U87 GSLCs M2rkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv6NlQhcA>? M3XBNWlEPTB;N{[2MlEyKM7:TdMg NUPnfXpiOjVzN{OyN|M>
U87MG M1vCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPYO|IhcA>? Mn;BTWM2OD1zNT62NlUh|ryPwrC= NH\zfXozPTB3MEmxOS=>
U251 NXnufnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNFAuPDByIN88US=> NXiz[oE{PDhiaB?= MXnEUXNQ NEO1[JBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYOwSFgzOjR4MkO3N|Y>
U87 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfUNVAxNTRyMDFOwG0> NYP1O452PDhiaB?= MXnEUXNQ MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIrFXIQzPDZ{M{ezOi=>
MDA-MB-231-br MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXwdmgxNTFyIN88US=> MlS2OFghcA>? NF;yToRFVVOR MnrUbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmHFNlQ3OjN5M{[=
HCC-1937 NWW0fmFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\EZVAuOzByIN88US=> M2LpNlQ5KGh? NFzte4dFVVOR NXjHfJdYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHjUblMzPDZ{M{ezOi=>
MDA-MB-231 NFzaOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\BNE01OCEQvF2= MXe0PEBp Mn3ESG1UVw>? M370NIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{\qfVI1PjJ|N{O2
MDA-MB-468 NHvSU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX4dXVOOC13MECg{txO MoixOFghcA>? MX\EUXNQ NGrV[4xqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1zHclI1PjJ|N{O2
T47D MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PyclAuOTByIN88US=> NI\hNlE1QCCq M2LoOWROW09? M{i4VYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{TLelI1PjJ|N{O2
MCF7 NX3WOJhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmzepM5OC1zMECwJO69VQ>? NIHOXJk1QCCq M3P1b2ROW09? M3\PNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEPkNFkzPDZ{M{ezOi=>
Hs683 M2DWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjCPVExNTFyMECg{txO M2DtfFk3KGh? NIPq[4dKSzVyPUGyPE46KM7:TR?= MnLxNlQ1QTV7MEe=
U87 NUPYdop{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKwMVExODBizszN NF[2Oos6PiCq NUXi[YFVUUN3ME2xPE41PSEQvF2= NWiwcllrOjR2OUW5NFc>
LNZ308 NGrDNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTKNnVtOC1zMECwJO69VQ>? MmfiPVYhcA>? M2PSbWlEPTB;M{K2Mlch|ryP NUHDUoR6OjR2OUW5NFc>
U87 MVzBdI9xfG:|aYOgRZN{[Xl? MWCxNFAh|ryP NFLiO2c1QCCq MXTEUXNQ MofCbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= MmfRNlQ1QDF3OE[=
U251  MoXjRZBweHSxc3nzJGF{e2G7 MnLzNVAxKM7:TR?= MlfOOFghcA>? M{jaR2ROW09? M2OwR4lv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= MX:yOFQ5OTV6Nh?=
U251 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M364flI1KGh? MUTJR|UxRTh4LkK55qCKyrIkgJmxMlU5KM7:TR?= MnzyNlQ{OjZ7NUS=
U251 NFTpOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4riO|Q5KGh? MnfqTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= MkTrNlQ{OjZ7NUS=
U251 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjMcZU4OiCq M3ftRmlEPTB;N{KuOFLjiIoEsfMAjVEvPDVizszN M13l[VI1OzJ4OUW0
U251 NY\1WXNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PZO|k3KGh? NGnsVFJKSzVyPU[5Mlgz6oDLwsJihKk{NjB2IN88US=> NF\FWFczPDN{Nkm1OC=>
T98G M4TaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6z[pREOC15NUCg{txO MXy3Nk86PiCq NHnEe3ZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXP4bGdCOjR|MkSwPFA>
U251-MG M3nac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW4NE05ODBizszN MW[3NkBp MYnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NYPqUGJEOjRyOUO2N|A>
D54-MG NITDbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjoNE05ODBizszN M3TmWlczKGh? M2G2UolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NES0TGkzPDB7M{[zNC=>
SHG-44 M3f0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Lqc|ExNTJyMDFOwG0> NVTH[YVoQTZiaB?= NIjx[plKSzVyPUmuO|MhyrFiMj6xNkDPxE1? NFPi[IszPDB4NUW2PS=>
U373  MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPkWGZuOTBvMkCwJO69VQ>? MoXuPVYhcA>? MVzJR|UxRTFyLkGzJOKyKDFwMEKg{txO NHrFRZYzPDB4NUW2PS=>
HT-29  NXj6T3dGTnWwY4Tpc44hSXO|YYm= NH63N2I2ODBizszN M1njfVI1NzR6IHi= NY\SZoJs\W6qYX7j[ZMhfGinIHzleoVteyCxZjFOt{1JOkG[wrC= NX\3fFJNOjRyM{iwOlg>
PC-3  MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfX[IQxNTJ3IN88US=> NXnEflRiPDhiaB?= NWC5Vm9OcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJJBwfGWwdHnheIVlKGK7IHz5Z49x\W6n MnPNNlM4PDZ7M{S=
PC-3  MkPmRZBweHSxc3nzJGF{e2G7 NYryd4JpOjVizszN M2DuZ|Q5KGh? NXrHeXNNcW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m NGPrZ4wzOzd2NkmzOC=>
T98G NUTsVJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm2bW42OC12MECg{txO NFW0PGgyPDRiaB?= M1K3bolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFHuS4gzOzdzNUS5PS=>
U87-MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnRXIZ1OTByINM1US=> NEG1ems4OiCq MlnFbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? M2rE[FI{Pjl4N{i4
U251-MG NV6yPZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTVV2t{OTByINM1US=> MXS3NkBp NUfvV3pycW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MWKyN|Y6Pjd6OB?=
LNT-229 M3fv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPI[XI{NTFyMDFOwG0> NWizeGw5OjRiaB?= NGDlb|ZqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXmzOYZJOjN4Nke2N|I>
T98G MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDwR3kyOC15MECg{txO MkDONlQhcA>? NIDiVZdqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWjKNY9KOjN4Nke2N|I>
U87  NIruVHNHfW6ldHnvckBCe3OjeR?= NXLYS4VUOTByINM1US=> NHrWZlU{KGh? MYjlcIV3[XSnczD0bIUhdGW4ZXzzJI9nKHCFaHuxJIFv\CCyQ3jrNi=> NX\5dmRUOjN4Nke0Olk>
HCT116 NHKzWmpHfW6ldHnvckBCe3OjeR?= NIS5N3gyODBiwsXN M2DSPVMhcA>? M1nGVYlv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w M{HzSlI{PjZ5NE[5
HCT3-6 MmDzSpVv[3Srb36gRZN{[Xl? MVuxNFAhyrWP MorxN{Bp M2[2R4lv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w MWGyN|Y3PzR4OR?=
U-87  NVPxWGplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ER|AuPDBizszN MXexNkBl M{HMeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXrwPFRXOjN4NEW3Nlk>
U-87  MVfBdI9xfG:|aYOgRZN{[Xl? MYKwMVQxKM7:TR?= NF;RcYI{NzZiZB?= NVTvUYNqcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NXv4SWR7OjN4NEW3Nlk>
U-87  M{WzWmZ2dmO2aX;uJGF{e2G7 NXq1NmwzOC12MDFOwG0> MWWzM|Yh\A>? NYPFSIhNcW6mdXPld{BifXSxcHjh[5khcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NVH3SZNOOjN4NEW3Nlk>
GB-SCC010 NGHhO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TPVlQh\A>? NUTjSJJPUUN3ME2yNlYh|ryP MV[yN|YyOjd3NR?=
GB-SCC026 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu4OnZbPCCm NH3NPFRKSzVyPUWzMlEh|ryP NH6zdoIzOzZzMke1OS=>
GB-SCC028 NV\mbI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzJdW54PCCm Mon6TWM2OD1zNkeg{txO M2XL[|I{PjF{N{W1
U87 NHTYXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\vcVQh\A>? M{PDT2lEPTB;NEWuNkDPxE1? MnP6NlM3OTJ5NUW=
U87 stem cell NWHhOXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vjTFQh\A>? NH3acWdKSzVyPU[2Mlch|ryP NVezc2pIOjN4MUK3OVU>

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02977780 Recruiting Glioblastoma Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology Inc.|Accelerate Brain Cancer Cure February 9 2017 Phase 2
NCT00392171 Completed Glioma|Astrocytoma|Oligodendroglioma|Glioblastoma Merck Sharp & Dohme Corp. June 9 2006 Phase 2
NCT00305864 Completed Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma National Cancer Institute (NCI)|Radiation Therapy Oncology Group February 9 2006 Phase 1|Phase 2
NCT00527657 Completed Brain Neoplasms|Melanoma M.D. Anderson Cancer Center|Celgene Corporation February 9 2006 Phase 1
NCT00200161 Completed Glioblastoma|Gliomas Memorial Sloan Kettering Cancer Center|Schering-Plough|Columbia University|Dana-Farber Cancer Institute August 9 2005 Phase 2
NCT03528642 Not yet recruiting Anaplastic Astrocytoma IDH-Mutant|Diffuse Astrocytoma IDH-Mutant|IDH1 Gene Mutation|IDH2 Gene Mutation National Cancer Institute (NCI) February 8 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID